Randomised phase 2 study comparing the efficacy and safety of the oral tyrosine kinase inhibitor nintedanib with single agent ifosfamide in patients with advanced, inoperable, metastatic soft tissue sarcoma after failure of first-line chemotherapy: EORTC-1506-STBSG “ANITA”-Reference-Cited by-同舟云学术

Randomised phase 2 study comparing the efficacy and safety of the oral tyrosine kinase inhibitor nintedanib with single agent ifosfamide in patients with advanced, inoperable, metastatic soft tissue sarcoma after failure of first-line chemotherapy: EORTC-1506-STBSG “ANITA”

Published:2021-07 Issue: Volume:152 Page:26-40
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Schöffski Patrick^ORCID,Toulmonde Maud,Estival Anna^ORCID,Marquina Gloria^ORCID,Dudzisz-Śledź Monika,Brahmi Mehdi,Steeghs Neeltje,Karavasilis Vasilios^ORCID,de Haan Jacco^ORCID,Wozniak Agnieszka^ORCID,Cousin Sophie,Domènech Marta,Bovée Judith V.M.G.,Charon-Barra Céline,Marreaud Sandrine,Litière Saskia,De Meulemeester Laura^ORCID,Olungu Christine,Gelderblom Hans

Funder

Boehringer Ingelheim International GmbH

European Organisation for Research and Treatment of Cancer

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference43 articles.

1. National Comprehensive Cancer Network. NCCN guidelines 1.2021 soft tissue sarcoma. Available at: https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf’.

2. Descriptive epidemiology of sarcomas in Europe: report from the RARECARE project;Stiller;Eur J Canc,2013

3. Treatment of advanced, metastatic soft tissue sarcoma: latest evidence and clinical considerations;In;Ther Adv Med Oncol,2017

4. Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up;Casali;Ann Oncol,2018

5. Soft tissue and bone tumours,2020

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Emerging innovations and advancements in the treatment of extremity and truncal soft tissue sarcomas;Journal of Surgical Oncology;2023-11-27

2. Clinical uses and safety concerns of tyrosine kinase inhibitors with a focus on novel drugs: A narrative review;Journal of Oncology Pharmacy Practice;2023-05-12

3. Renal adverse reactions of tyrosine kinase inhibitors in the treatment of tumours: A Bayesian network meta-analysis;Frontiers in Pharmacology;2022-11-03

4. What’s the latest with investigational drugs for soft tissue sarcoma?;Expert Opinion on Investigational Drugs;2022-11-02

5. Tyrosine kinase inhibitors in sarcoma treatment (Review);Oncology Letters;2022-04-21